Bobcat339: Precision Cytosine-Based TET Inhibitor for Epigenetics

Executive Summary: Bobcat339 is a small-molecule cytosine analog that selectively inhibits TET1 and TET2 enzymes, pivotal for DNA demethylation, with verified IC50 values of 33 μM and 73 μM, respectively (product specification). This compound enables researchers to modulate DNA methylation and gene transcription in a controlled, reproducible manner. Its solid-state formulation and 98% purity, as provided by APExBIO, ensure experimental consistency (product information). Integration of Bobcat339 into epigenetics workflows supports mechanistic studies of disease states such as osteoporosis, where methylation and enhancer dynamics are central (reference study). Its selectivity profile and practical handling recommendations distinguish it from less specific or less stable DNA demethylation inhibitors.

Biological Rationale

DNA methylation, the covalent addition of a methyl group to the fifth carbon of cytosine to form 5-methylcytosine (5-mC), is a fundamental epigenetic modification regulating gene expression and cellular identity (reference study). TET (Ten-Eleven Translocation) enzymes catalyze the iterative oxidation of 5-mC, initiating active DNA demethylation. Aberrant DNA methylation patterns are linked to diseases such as cancer and osteoporosis (related article). In mesenchymal stem cells (MSCs), TET activity modulates osteogenesis by influencing enhancer landscapes and autophagy pathways ( reference study). By selectively inhibiting TET1 and TET2, Bobcat339 allows researchers to precisely interrogate the relationship between DNA methylation, enhancer function, and gene transcription in both physiological and disease contexts.

Mechanism of Action of Bobcat339

Bobcat339 is a cytosine structure-based small molecule, formally named 1-([1,1'-biphenyl]-3-yl)-4-amino-5-chloropyrimidin-2(1H)-one (C₁₆H₁₂ClN₃O, MW 297.74). It competitively binds to the active site of TET family enzymes, inhibiting their ability to catalyze the oxidation of 5-mC to 5-hydroxymethylcytosine. Bobcat339 exhibits selectivity for TET1 (IC50: 33 μM) and TET2 (IC50: 73 μM), with negligible off-target activity against other epigenetic regulators (product specification). This inhibition stabilizes 5-mC marks and prevents DNA demethylation, thereby affecting downstream gene transcription and chromatin remodeling (related article). The compound's cytosine-mimicry underlies its target specificity and distinguishes it from broader-spectrum demethylation agents.

Evidence & Benchmarks

• Bobcat339 inhibits TET1 with an IC50 of 33 μM and TET2 with an IC50 of 73 μM under standard assay conditions (pH 7.4, 25°C, as reported in the product technical sheet).
• DNA demethylation inhibitors such as Bobcat339 modulate gene expression by stabilizing 5-mC at regulatory elements, as established by whole-genome bisulfite sequencing in disease models (reference study).
• In senile osteoporosis models, manipulating DNA methylation at super-enhancers affects osteogenesis and autophagic flux in MSCs (reference study).
• Bobcat339's solid form and 98% purity are validated by analytical HPLC and MS in each supplied batch (product specification).
• Long-term solution storage is discouraged; solutions should be freshly prepared to maintain inhibitor stability and potency (product handling guide).

This article extends upon prior overviews of Bobcat339 by offering granular, quantitative benchmarks and explicit protocol considerations for TET inhibition, updating the scenario-driven insights previously summarized in 'Reliable TET Inhibition for Advanced Epigenetics'.

Applications, Limits & Misconceptions

Bobcat339 is optimized for:

• Epigenetics research compound applications requiring selective inhibition of TET1/TET2 in vitro or ex vivo.
• DNA methylation regulation studies in stem cell differentiation, especially osteogenesis (reference study).
• Gene transcription modulation workflows to dissect direct methylation-dependent regulatory networks.
• Mechanistic studies of epigenetic regulatory mechanisms in disease models such as osteoporosis, as highlighted by the UHRF1–TGM2–autophagy axis (internal article).

Compared with broader demethylation agents, Bobcat339 provides higher selectivity and experimental reproducibility (related article). This article clarifies how Bobcat339's quantitative selectivity benchmarks and handling protocols improve upon workflows outlined in general epigenetics reviews.

Common Pitfalls or Misconceptions

• Not a pan-TET inhibitor: Bobcat339 shows selectivity for TET1 and TET2; it is not validated for TET3 inhibition (specification).
• Not suitable for in vivo systemic dosing: No peer-reviewed data support efficacy or safety for systemic animal or human administration.
• Solution instability: Stock solutions degrade rapidly; always use fresh aliquots (handling guide).
• Not a DNA methyltransferase inhibitor: Bobcat339 targets demethylation, not methyltransferase activity.
• Results context-dependent: Gene expression effects depend on cell type and methylation landscape; benchmarking is essential for each application (related article).

Workflow Integration & Parameters

For optimal use of Bobcat339 (APExBIO SKU BA4643), apply these protocol parameters:

Protocol Parameters

• Compound preparation: Dissolve solid Bobcat339 in DMSO to a stock concentration of 10 mM; filter-sterilize if required (product information).
• Storage: Store solid at -20°C, protected from light; ship with blue ice. Use solutions within 24 hours to ensure potency.
• In vitro dosing: Typical experimental ranges are 10–100 μM, with 33–73 μM required for TET1/TET2 inhibition; titrate per cell type (specification).
• Assay controls: Include vehicle (DMSO) controls in each experiment to account for solvent effects.
• Endpoint quantification: Assess DNA methylation by bisulfite sequencing or 5-mC immunodetection after 24–72 h incubation.

For advanced troubleshooting, see 'Cytosine Structure-Based TET Enzyme Inhibitor in Action', which provides scenario-driven workflow advice. This article updates those recommendations with explicit IC50 and stability benchmarks for Bobcat339.

Conclusion & Outlook

Bobcat339, as supplied by APExBIO, sets a new benchmark for selective, reproducible TET1 and TET2 inhibition in epigenetics research. Its quantitative selectivity, robust handling guidelines, and validated purity support its use in mechanistic studies of DNA methylation regulation and gene transcription modulation. The integration of Bobcat339 into workflows focused on osteogenesis, enhancer dynamics, and stem cell biology is grounded in rigorous multi-omics data and practical experience (reference study). As the field advances, Bobcat339’s specificity and stability will remain critical for dissecting epigenetic regulatory mechanisms and for the translational development of new therapeutic strategies targeting methylation-dependent disease processes.